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Abstract
Background: The cholinergic anti-inflammatory pathway (CAP) primarily functions through acetylcholine (ACh)-alpha7
nicotinic acetylcholine receptor (α7nAChR) interaction on macrophages to control peripheral inflammation.
Interestingly, ACh can also bind α7nAChRs on microglia resulting in neuroprotective effects. However, ACh effects on
astrocytes remain elusive. Here, we investigated the effects of nicotine, an ACh receptor agonist, on the cytokine and
cholinesterase production of immunocompetent human astrocytes stimulated with interleukin 1β (IL-1β) in vitro.
In addition, the potential involvement of prostaglandins as mediators of nicotine was studied using cyclooxygenase 2
(COX-2) inhibition.
Methods: Cultured human fetal astrocytes were stimulated with human recombinant IL-1β and treated simultaneously
with nicotine at different concentrations (1, 10, and 100 μM). Cell supernatants were collected for cytokine and
cholinesterase profiling using ELISA and MesoScale multiplex assay. α7nAChR expression on activated human
astrocytes was studied using immunofluorescence. For the COX-2 inhibition studies, enzyme activity was inhibited
using NS-398. One-way ANOVA was used to perform statistical analyses.
Results: Nicotine treatment dose dependently limits the production of critical proinflammatory cytokines such as IL-6
(60.5 ± 3.3, %inhibition), IL-1β (42.4 ± 1.7, %inhibition), and TNF-α (68.9 ± 7.7, %inhibition) by activated human
astrocytes. Interestingly, it also inhibits IL-8 chemokine (31.4 ± 8.5, %inhibition), IL-13 (34.243 ± 4.9, %inhibition), and
butyrylcholinesterase (20.8 ± 2.8, %inhibition) production at 100 μM. Expression of α7nAChR was detected on the
activated human astrocytes. Importantly, nicotine’s inhibitory effect on IL-6 production was reversed with the specific
COX-2 inhibitor NS-398.
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Conclusions: Activation of the cholinergic system through α7nAChR agonists has been known to suppress
inflammation both in the CNS and periphery. In the CNS, earlier experimental data shows that cholinergic activation
through nicotine inhibits microglial activation and proinflammatory cytokine release. Here, we report similar
anti-inflammatory effects of cholinergic activation on human astrocytes, at least partly mediated through the COX-2
pathway. These results confirm the potential for cholinergic neuroprotection, which is looked upon as a promising
therapy for neuroinflammation as well as neurodegenerative diseases and stroke. Our data implicates an important role
for the prostaglandin system in cholinergic regulatory effects.
Keywords: Nicotine, Astrocytes, Prostaglandins, Cyclooxygenase 2, Cholinergic immune regulation, Alpha7 nicotinic
acetylcholine receptor, Neuroinflammation
Background
Inflammation plays a crucial role in our self-defense and
is orchestrated by a series of well-characterized immune
responses to eliminate the invading pathogen. While the
initiation of an immune response is of paramount
importance to keep life-threatening diseases at bay, a
failure in resolving inflammation and restoring homeosta-
sis after the threat is eliminated ultimately results in
chronic inflammation and puts the organism in jeopardy.
Thus, inflammation is a double-edged sword and needs to
be closely monitored by the innate anti-inflammatory
mechanisms. One such mechanism, which was discovered
few decades ago and is now looked upon as a promising
therapy to treat chronic inflammatory diseases, is called
the “cholinergic anti-inflammatory pathway” (CAP) (for a
review, see [1]).
The CAP is believed to be a highly conserved mechan-
ism in which the central nervous system (CNS) exhibits
its anti-inflammatory role in the periphery through the
efferent vagus nerve in a discrete and localized manner
where inflammation had typically originated. Acetylcho-
line (ACh), the principal neurotransmitter of CAP re-
leased by splenic T lymphocytes in response to the
efferent vagus nerve activation, acts on specific α7
nicotinic acetylcholine (α7nACh) receptors on activated
macrophages to inhibit the release of proinflammatory
cytokines, thereby limiting peripheral inflammation [1].
On the other hand, afferent activation of the vagus nerve
has been shown to increase ACh release in the brain,
mediated by adrenergic activation of the central cho-
linergic network [2–4]. One of the important effects for
the centrally released ACh is to specifically bind to
α7nACh receptors on microglia, thereby promoting anti-
inflammatory and neuroprotective effects in CNS [5]. The
latter has been well documented [6–8], and different
agonists for nicotinic acetylcholine receptors (nAChRs; α7
subtype in particular) are now in clinical trials for treat-
ment of neurodegenerative diseases.
nAChRs are widely expressed by cells in the central and
peripheral nervous systems, immune system, and other
peripheral tissues. In the CNS, both neuronal and non-
neuronal cells that include astrocytes, microglia, oligoden-
drocytes, and endothelial cells express α7nAChR [9].
While nAChRs, in general, are known to participate in
memory, learning, locomotion, and many other physio-
logical functions, activation of α7nAChRs have been
linked to neuroprotection and neuron survival [10, 11].
Interestingly, mechanistic studies on the downstream
effects of nicotine-α7nAChR interaction in rat microglia
revealed an up-regulation of cyclooxygenase 2 (COX-2)
and prostaglandin E2 (PGE2) synthesis, implicating prosta-
glandins (PGs) as one of the important mediators of
cholinergic effects in the CNS [6]. However, the
magnitude of these effects, and their impact on other
resident CNS cells such as astrocytes, is largely unknown.
PGE2 is a bioactive lipid molecule produced by the action
of cyclooxygenases (COX-1/2) and terminal synthases
(microsomal prostaglandin E synthases (mPGES-1 and
mPGES-2) and cytosolic prostaglandin E2 synthase
(cPGES)) on arachidonic acid released from the cell
membrane by phospholipase A2 following physiological or
inflammatory stimuli.
Astrocytes are the most abundant glial cells in the CNS
and also confer important roles in neuroinflammation.
These resident cells produce a plethora of cytokines such
as interleukin 1β (IL-1β) and interleukin 6 (IL-6) which are
implicated in several neurodegenerative diseases [12, 13].
In addition, astrocytes also happen to be a major source of
one of the key ACh-hydrolyzing enzymes, butyrylcholines-
terase (BuChE). Increased BuChE expression is strongly
correlated with activation of astrocytes [14]. However, the
role of the other ACh-hydrolyzing enzyme acetylcholin-
esterase (AChE) with respect to astrocytes remains unclear.
In fact, both CSF and plasma BuChE and AChE levels are
elevated in many clinical ailments [15]. On the contrary,
astrocytes can also secrete anti-inflammatory cytokines
such as transforming growth factor β (TGFβ), which in
turn can limit microglial activation during inflammation
[16, 17]. Intriguingly, astrocytes have been shown to ex-
press α7nACh receptors whose activation mediates
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neuroprotective effects (against neuroinflammation) fol-
lowing nicotine administration [18]. It is important to note
that these observations were made in mice and hence one
can question their relevance to humans. Thus, the need to
investigate and confirm nicotine’s effects on activated
human astrocytes demands attention.
In the present study, we aimed to activate human fetal
astrocytes with recombinant IL-1β and study the effects
of nicotine on the proinflammatory cytokine and cholin-
esterase (AChE and BuChE) production. In addition,
downstream mechanisms of nicotine’s action were
studied with a focus on the prostaglandin pathway,
earlier known from peripheral immune cells to be in-
volved in cholinergic immunomodulatory effects.
Methods
Human fetal astrocytes culture and treatment
Cryopreserved primary human fetal astrocytes (approx. 1
million cells, SC1800, ScienCell Research Laboratories
purchased from 3H Biomedical AB, Sweden) were cul-
tured in poly-L-lysine-coated T-175 flasks as per supplier’s
instructions. Cells were incubated in a humidified incuba-
tor with 5 % CO2 at 37 °C, and astrocyte medium supple-
mented with fetal bovine serum, astrocyte growth
supplement, and penicillin-streptomycin (SC1801, Scien-
Cell Research Laboratories purchased from 3H Biomed-
ical AB, Sweden) was changed once every 2 days till the
cells reached 80–90 % confluency. Later, the cells were
split using trypsin-EDTA and seeded in poly-L-lysine-
coated 6 well plates (20,000 cells/well) or chamber slides
(8000 cells/well). One day prior to treatment, the
complete medium was replaced with serum-starved
medium. The next day, cells were stimulated with IL-1β
(10 ng/ml, PHC0815, Invitrogen) and nicotine (1, 10, and
100 μM, N3879, Sigma) simultaneously. In the COX-2
inhibition studies, NS-398 (1 or 10 μM, Cayman Chem-
ical) was added to the cells 30 min prior to the treatment
mentioned above. After 20 h, cell supernatants were
collected, centrifuged, and stored at −20 °C for further
use. The cells on the chamber slides were formaldehyde-
or acetone fixed for glial fibrillary acidic protein (GFAP)
and α7nAChR staining, respectively, air dried, and stored
at −80 °C. Cell cultures were tested negative for myco-
plasma contamination.
Immunofluorescence for characterizing astrocytes and
co-localization with α7nACh receptor
Formaldehyde-fixed slides were taken out from −80 °C
storage and were washed with PBS-saponin. Following
that, the slides were incubated overnight at 4 °C with pri-
mary mouse monoclonal antibodies against GFAP (8152,
Cell Signaling) tagged with Alexa Fluor 594 in a 1:50
dilution containing 3 % normal human serum. For asses-
sing co-localization of GFAP and α7nACh receptor
expression, in addition to GFAP primary antibodies, the
cells were also incubated overnight with rabbit polyclonal
against α7nACh receptor (1:500, ab10096, Abcam). Later,
the cells were treated with biotinylated goat anti-rabbit
(1:1600, Vector Laboratories) for 30 min. Then, they were
incubated with streptavidin antibodies conjugated with
Alexa Fluor 488 (1:1000) for 45 min. The slides were later
rinsed, incubated with 4′,6-diamidino-2-phenylindole
(DAPI, 1:2000) for 1 min at room temperature and
mounted using PBS-glycerol. The slides were examined
under a microscope (Leica Microsystems, Cambridge,
UK), and images were taken at ×20 or ×40 magnification.
Cytokine measurement using sandwich enzyme-linked
immunosorbent assay
The cytokine concentrations in the culture supernatants
were measured using human IL-6 (DuoSet, DY206) and IL-
8 (DuoSet, DY208) from R&D Systems. The detection range
for IL-6 and IL-8 cytokine measurement is 9.38–600 and
31.20–2000 pg/ml, respectively. Microtiter plates were incu-
bated with 100 μl of capture antibody (mouse anti-human
IL-6 or IL-8) per well overnight at room temperature. Next,
the plates were washed with PBS-Tween as per instructions
and incubated for an hour with blocking solution. Following
that, 100 μl of the samples and standards were added to the
wells and incubated at room temperature. After 2 h, the
wells were washed and incubated with detection antibodies
(biotinylated goat anti-human IL-6 or IL-8) for 2 h. Later,
streptavidin-HRP and substrate solutions were added and
incubated as per protocol. Finally, the plates were read at
450 nm with the correction wavelength at 570 nm. The
samples were diluted accordingly to comply with the detec-
tion limits of the assay kits.
Measurement of Th1 and Th2 cytokines
We measured interferon (IFN)-γ, IL-1β, IL-2, IL-4, IL-6,
IL-8, IL-10, IL-12p70, IL-13, and TNF-α levels in the cell
supernatants using the ultrasensitive MesoScale Discov-
ery (MSD) MULTI-SPOT assay (Human Proinflamma-
tory Panel 1, K15049D, MSD). The detection range is
0.36–1460, 0.12–495, 0.36–1460, 0.05–198, 0.19–767,
0.12–495, 0.08–334, 0.10–421, 0.11–466, and 0.08–
312 pg/ml, respectively. This is a sandwich immunoassay
where 50 μl of the samples and standards are first added,
as technical duplicates, to the pre-coated plates and
incubated overnight at 4 °C. Next, the plates were
washed to remove unbound substances and incubated
with electrochemiluminescent conjugated detection anti-
bodies for 2 h at room temperature. The plates are then
treated with MSD buffer and read using a MSD instru-
ment (SECTOR Imager 2400). The standards for differ-
ent cytokines vary in their range and are hence tailored
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according to the possible quantities that might be de-
tected for an individual cytokine.
Immunohistochemistry for α7nACh receptor expression
Acetone-fixed human astrocytes, treated with IL-1β and
nicotine, were stained for the expression of the α7nACh
receptor. The slides were first washed in PBS-0.1 %
saponin solution at room temperature. Then, endogenous
hydrogen peroxidase enzyme activity and avidin and biotin
binding sites were blocked using 1 % hydrogen peroxide
and avidin-biotin blocking kit, respectively. The slides were
then blocked with 3 % normal goat serum to avoid any
non-specific binding. The slides were washed three times
lasting 3 min each. The primary antibody against the
α7nACh receptor (1:1200, monoclonal rat anti-human,
ab24644, abcam) containing 3 % normal human serum
was added to the slides and incubated overnight at 4 °C.
The next day, the slides were washed and incubated with
1 % normal goat serum followed by incubation with sec-
ondary antibodies (biotinylated anti-rat IgG raised in goat,
Vector Laboratories) for 30 min at room temperature. The
signal for the protein expression was developed using the
avidin-biotin complex (ABC complex, Vector Laboratories)
and DAB substrate kit (3,3′-diaminobenzidine and H2O2,
Vector Laboratories). Finally, the slides were mounted
using PBS-glycerol and viewed under a fluorescence micro-
scope (Leica Microsystems, Cambridge, UK). Photomicro-
graphs (×20 or ×40) of the labeled regions were obtained
using the Leica Application Suite (LAS version 4.4). Rat
IgG antibodies were used as isotype control.
Enzyme immunoassay for PGE2 quantification
Prostaglandin E2 levels in the cell supernatants were
measured using a forward sequential competitive binding
technique in which the analyte competes with horseradish
peroxidase (HRP)-conjugated PGE2 to bind to a specific
number of sites on a mouse monoclonal antibody (Prosta-
glandin E2 Parameter Assay Kit, KGE004B, R&D Systems).
First, the samples, standards, and controls were allowed to
bind to the antibody pre-coated on the plate for an hour.
After the incubation, the HRP-conjugated PGE2 was added
to the wells where it binds to the remaining binding sites
on the plate. A substrate solution, to quantify the bound
HRP activity, was added to all wells following a wash that
removed unbound substances. The absorbance of the color,
thus developed, was measured at 450 nm.
Prostaglandin analysis by Liquid chromatography tandem
mass spectrometry (LC-MS/MS)
Prostaglandins in cell supernatants were extracted and
analyzed according to Idborg et al. [19]. Working in dupli-
cates, 450 μl of samples were spiked with 50 μl deuterated
internal standards of 6-keto-PGF1α, PGF2α, PGE2, PGD2,
TxB2, and 15-deoxy-Δ12,14PGJ2 (Cayman Chemical
Company) and made acidic with 500 μl 0.2 % formic acid
(FA) in Milli-Q. The samples were loaded on Oasis HLB
1 cc 30 mg cartridge (Waters Corporation, MA, USA) that
had been preconditioned with methanol and 0.05 % FA in
Milli-Q. Prostaglandins were eluted in 1 ml methanol and
evaporated to dryness under vacuum. Samples were stored
at −20 °C until resuspended in 50 μl 7 % acetonitrile prior
to analysis with LC-MS/MS. The extracted prostaglandins
were quantified using a triple quadrupole mass spectrom-
eter (Acquity TQ Detector, Waters Corporation) equipped
with a Waters 2795 HPLC (Waters Corporation). Separ-
ation was performed on a 100 × 2.0 mm Synergi 2.5 μm
Hydro-RP 100 Å column (Phenomenex, CA, USA) with a
45-min stepwise linear gradient (10–90 %) of 0.05 % FA in
acetonitrile as mobile phase B and Milli-Q as mobile phase
A. Individual prostaglandins were detected in multiple
reaction monitoring mode. Data were analyzed using
MassLynx Software, version 4.1, with internal standard
calibration and quantification to external standard curves.
Measurement of AChE and BuChE in cell supernatants
Protein concentration of AChE and BuChE in the astrocyte
culture supernatants was measured using quantitative
sandwich ELISA technique employed in human acetyl-
cholinesterase (DACHE0) and human butyrylcholinester-
ase (DBHE0) quantikine ELISA kits (R&D Systems). The
detection ranges are 125–8000 pg/ml for AChE and
0.156–10 ng/ml for BuChE. Briefly, undiluted samples and
standards were added to the microplate strips pre-coated
with monoclonal antibodies specific for human AChE and
BuChE and incubated for 2 h at room temperature.
Following this, plates were washed as per manufacturer’s
protocol and incubated with conjugate for two more hours.
After the last wash, the plates were incubated with the sub-
strate solution and the plates were read after 30 min at
450 nM, and the reference wavelength was set to 540 nM.
Statistics
All experiments were repeated at least three to five times
unless otherwise indicated. Samples were run in duplicates
for all our assays, and corresponding data are represented
as mean ± SEM. Statistical analyses were performed using
one-way ANOVA with unpaired Student’s t test as men-
tioned, and the significance was set at p value <0.05. All
the statistical tests were done using GraphPad Prism 6.0
software.
Results
Expression of glial fibrillary acidic protein in human
astrocyte cultures
First, we confirmed the identity of the human fetal astro-
cytes by examining the expression of the most predom-
inant astroglial marker glial fibrillary acidic protein
(GFAP), an intermediate filament protein by using
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immunofluorescence. Our astrocyte cultures displayed
strong GFAP expression both in the resting and
activated states as shown in Fig. 1. We quantified the
GFAP-positive cells to be approximately 93 % of the
total cells. Our results thus confirmed the manufac-
turer’s claim that more than 90 % of the cells were
positive for GFAP expression. The possibility of non-
specific staining was ruled out using an appropriate
negative control.
Kinetics of IL-6 release by human astrocytes activated
with IL-1β
Next, human astrocytes were stimulated with IL-1β
(10 ng/ml) for 0, 2, 4, 6, 16, 20, and 24 h. Measurement of
IL-6 release in the cell supernatants revealed that IL-1β
increased IL-6 levels fourfold compared to the control as
early as 4 h after treatment (604.8 ± 159.2 vs 139.6
±55.9 pg/ml, p = 0.05) and steadily increased manyfold
thereafter. The peak for IL-6 production was reached at
20 h of IL-1β treatment (27,698.5 ± 7215.96 vs 214.96
±71.94 pg/ml, p < 0.05) (Fig. 2a).
Nicotine treatment significantly inhibits IL-6 release by
human astrocytes
We incubated the IL-1β activated human astrocytes with
nicotine at various concentrations (1, 10, and 100 μM)
for 6, 20, and 48 h respectively. As mentioned earlier,
IL-1β was found to induce significant levels of IL-6
release in the supernatant compared to the control.
Interestingly, nicotine dose dependently downregulated
IL-6 production at 20 h. The inhibition was up to 49.5 ±
9.5 % at 100 μM nicotine concentration as displayed in
Fig. 2b. In addition, nicotine alone did not exert any ef-
fect on the IL-6 release by human astrocytes (data
not shown).
Effects of nicotine on Th1/Th2 cytokine production by
human astrocytes
Following the limiting effects of nicotine on IL-6 release
by human astrocytes after incubation for 20 h, we aimed
to measure the levels of various other cytokines associ-
ated with IL-1β mediated inflammation. Using a multi-
plex assay, we reconfirmed the effects on IL-6 release.
Interestingly, as illustrated in Fig. 3, we discovered that
nicotine had similar immunomodulatory effects on
TNF-α (68.9 ± 7.7, %inhibition at 100 μM nicotine treat-
ment, p < 0.05), IL-1β (42.4 ± 1.7, %inhibition at 1, 10,
and 100 μM nicotine treatment, p < 0.01), IL-8 (31.4 ±
8.5, %inhibition at 100 μM nicotine treatment, p < 0.05),
and IL-13 (34.243 ± 4.9, %inhibition at 100 μM nicotine
treatment, p < 0.05) cytokines. On the contrary, nicotine
did not affect the production of the other cytokines
measured including IFN-γ, IL-2, IL-4, IL-10, and IL-
12p70 which were, in fact, secreted at low levels after
IL-1β stimulation (data not shown).
Nicotine decreases BuChE protein release from activated
human astrocytes
We measured acetylcholinesterase (AChE) and butyrylcho-




Fig. 1 Characterization of cultured human cortical astrocytes using immunofluorescence. Human astrocytes were identified using GFAP
monoclonal antibody (Alexa Fluor 594, red) and DAPI (blue). Fluorescence microscopy images of human astrocytes taken at a ×20 representing
GFAP-positive (93 %) human astrocytes and b ×40 magnification
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astrocyte supernatants following nicotine treatment (1, 10,
and 100 μM) for 20 h. BuChE was detectable in all treat-
ment supernatants as shown in Fig. 4. Human astrocytes
released BuChE into the supernatant even under normal
conditions. Nicotine treatment reduced BuChE levels at
100 μM (79.3 ± 2.8, % fold change compared to IL-1β treat-
ment alone). Moreover, we observed a tendency of dose-
dependent nicotine-induced reduction of BuChE levels. IL-
1β alone did not have any significant effects on BuChE pro-
tein levels when compared to the control. AChE was not
detected in any of the cell culture supernatants.
Expression of α7nAChR in activated human astrocytes
Next, we studied the expression of the α7nACh receptor
in IL-1β-activated human astrocytes treated with nico-
tine. We could confirm astrocyte expression of the
α7nACh receptor protein with or without nicotine at
various concentrations as shown in Fig. 5. Isotype and
secondary antibodies alone did not show any positive
signal reducing the possibility of non-specific binding.
Furthermore, using immunofluorescence, we could dem-
onstrate that nicotine-activated GFAP-positive human
astrocytes displayed a strong expression of α7nACh
receptor (Fig. 6).
Nicotine treatment promotes human astrocytes to release
more prostaglandin E2
Known for its close association with IL-1β-initiated
inflammation and human astrocytes, PGE2 production
was quantified in the culture supernatants accordingly.
Intriguingly, IL-1β-induced PGE2 release by activated
human astrocytes further tends to increase after incuba-
tion with nicotine (204.88 ± 41.77 at 1 μM, 287.15 ±
108.36 at 10 μM, and 251.94 ± 71.09 at 100 μM; % fold
increase compared to IL-1β treatment alone, Fig. 7).
Nicotine alone did not induce PGE2 above detectable
levels (data not shown).
(a)
(b)
Fig. 2 Kinetics and inhibition of IL-6 release by human astrocytes in response to IL-1β and nicotine treatment. a IL-6 concentration in the cell
culture supernatants collected at 2, 4, 6, 16, 20, and 24 h was assessed using sandwich ELISA. Values are represented as mean ± SEM of three
independent experiments performed in duplicates. Statistical analyses was done using Student’s t test.(*p < 0.05). b Cell culture supernatants of
activated human astrocytes treated with nicotine at different concentrations for 6, 20, and 48 h were analyzed for IL-6 levels using sandwich
ELISA. Samples were run as duplicates, and values are represented as mean ± SEM from at least three independent experiments (n = 3 for 6 h,
n = 6 for 20 h, and n = 4 for 48 h). Data is presented in terms of fold change compared to the IL-6 level following IL-1β treatment. Following
20-h nicotine treatment, IL-6 protein levels were downregulated dose dependently in the cell supernatants. Statistical analyses was performed
using one-way ANOVA (****p < 0.0001, **p < 0.01, *p < 0.05)
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COX-2 inhibition reverses nicotine effects on human
astrocytes
Then, we investigated the effects of COX-2 inhibition on
the immunomodulatory effects of nicotine on IL-6 cyto-
kine production in activated human astrocytes. COX-2
activity was blocked using NS-398 at 1 and 10 μM. Cells
exposed to NS-398 failed to reduce the IL-6 release in
the presence of nicotine (10 μM) as shown in Fig. 8a.
Furthermore, incubation with only NS-398 did not ex-
hibit any effects on the astrocytes. LC-MS/MS studies
on the cell culture supernatants were performed to
measure the PGE2 production following NS-398 treat-
ment, and the results are demonstrated in Fig. 8b. In ac-
cordance with our previous observations, nicotine tends
to increase IL-1β-induced PGE2 release (119.66 ± 14.4, %
fold change compared to IL-1β treatment alone). In
addition, a complete inhibition of PGE2 production was
observed in the cells treated with NS-398. On the con-
trary, other members of the prostanoid family were at
undetectable levels. Dimethylsulfoxide (DMSO) used to
dissolve NS-398 did not have any effects on its own.
Nicotine treatment alone did not induce PGE2 (data not
shown).
Fig. 3 Modulating effects of nicotine on multiple cytokines during neuroinflammation. Activated human astrocytes were treated with nicotine
at 1, 10, and 100 μM for 20 h, and their supernatants were collected. Cytokine profiling related to Th1/Th2 immune response was performed
using multiplex cytokine ELISA and human IL-8 sandwich ELISA. Samples were run as duplicates, and values are represented as mean ± SEM
from at least three independent experiments (n = 3 for multiplex ELISA and n = 6 for sandwich ELISA). Data is presented in terms of fold change
compared to cytokine levels following IL-1β treatment. Nicotine treatment significantly reduced the production of IL-6, TNF-α, IL-1β, IL-13, and
chemokine IL-8. Statistical analyses was performed using one-way ANOVA (****p < 0.0001, **p < 0.01, *p < 0.05)
IL-1 (10ng/ml) - + + + +



















Fig. 4 Butyrylcholinesterase levels in cell culture supernatants of IL-1β
activated human astrocytes following nicotine treatment. Both untreated
and IL-1β-activated human astrocytes released similar BuChE protein levels
into their supernatants following 20-h incubation. Nicotine dose depend-
ently inhibited BuChE protein release by activated human astrocytes. Sam-
ples were run as duplicates, and values are represented as mean ± SEM of
four independent experiments. Data is presented in terms of fold change
compared to BuChE levels following IL-1β treatment
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Discussion
Cholinergic signaling comprises a network of effects both
on resident cells in the CNS and immune cells entering the
brain. Activation of the central cholinergic system, for ex-
ample, by afferent electrical vagus nerve stimulation [2, 3],
was earlier shown to exhibit neuroprotective effects
mediated by α7nAChR on activated microglia [5, 11].
Potential immunoregulatory cholinergic systems on other
immunocompetent cells in the CNS such as astrocytes
remain elusive. In the present study, we focused on the
potential effects of CAP activation through the administra-
tion of cholinergic agonists on human astrocytes, which
IL-
(a)
(d) (g)IL- IL-IL- 1 +Nicotine 100µM1 +Nicotine 10µM 1 +Nicotine 100µM1





Fig. 5 Expression of α7 nicotinic acetylcholine receptor on activated human astrocytes. Human astrocytes grown on chamber slides were
incubated with IL-1β and nicotine for 20 h and later fixed in paraformaldehyde for immunohistochemistry. Positively stained cells appear brown
in the images. Cells both a untreated and d–f treated with nicotine displayed specific staining for α7nACh receptor protein expression whereas
cells stained with b unspecific antibody raised in rat (isotype) and c goat anti-rat (secondary antibody) alone displayed no specific staining.
Representative images were taken at ×25 (a–f) and ×40 (g) magnification under the microscope
GFAP 7nAChR DAPI
Merged
Fig. 6 Co-localization of α7 nicotinic acetylcholine receptor on activated human astrocytes treated with nicotine. Double immunofluorescence
images showing the expression of astroglial marker GFAP (red), α7nACh receptor (green), and nucleus (blue). Representative images were taken at
×40 magnification under the microscope
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are immunocompetent effector cells capable of antigen
presentation and cytokine and chemokine production
during CNS inflammation [12]. We found that incubation
with nicotine has immunosuppressive effects on the
production of proinflammatory cytokines in IL-1β-
activated human fetal astrocytes. Moreover, a higher dose
of nicotine limits the production of the chemokine IL-8
and tends to inhibit non-specific cholinesterase enzyme
BuChE. In addition to being responsive to nicotine treat-
ment, activated human astrocytes also expressed
α7nAChR. Interestingly, the immunomodulatory effects of
nicotine on astrocytes were reversed with COX-2 inhib-
ition, suggesting prostaglandins as important mediators in
this context (Fig. 9).
When testing different ways for astrocyte activation in
vitro, we first found, in agreement with earlier data [20,
21], that human fetal astrocytes in contrast to mouse as-
trocytes failed to respond to lipopolysaccharides (LPS).
However, another mediator known to exert functional
effects on astrocytes is IL-1β. Elevated levels of IL-1β
have been shown to induce IL-6 and TNF-α production
in astrocytes thereby propagating further inflammation
and resulting in neuronal death [20, 22]. As expected,
activation of primary human fetal astrocytes with IL-1β
induced astrogliosis defined by proliferation, morpho-
logical changes, and enhanced GFAP expression (data
not shown). Furthermore, supporting the earlier studies
[20, 21, 23], we could detect an IL-1β-induced increase
in the levels of NF-κB-dependent inflammatory proteins
IL-6 and TNF-α production.
IL-6 is a major cytokine in the CNS with both benefi-
cial and destructive outcomes. It is well established to be
actively involved in astrogliosis following an inflamma-
tory insult [24, 25]. Furthermore, dysregulation in IL-6
expression leading to its excess in the CNS has been
Fig. 7 Prostaglandin E2 synthesis in human astrocytes induced by
nicotine treatment. Cell culture supernatants were assayed for PGE2
levels using enzyme immunoassay (EIA). IL-1β-induced PGE2 synthesis
in human astrocytes and treatment with nicotine increased it further
dose dependently. Samples were run as duplicates, and PGE2 levels
following various treatments are represented as mean ± SEM from four
independent experiments. Data is presented in terms of fold change
compared to cytokine levels following IL-1β treatment
(a) (b)
Fig. 8 Role of COX-2 during the effects of nicotine on IL-6 release from activated human astrocytes. a Inhibition of cyclooxygenase 2 activity by using
NS-398 (1 and 10 μM) reversed the effects of nicotine on IL-6 release from activated human astrocytes. The COX-2 inhibitor failed to affect IL-1β-induced
IL-6 production on its own. b Cell culture supernatants were analyzed for prostaglandin profiling using LC-MS/MS. IL-1β induced high levels of PGE2
production that further increased with nicotine treatment. PGE2 synthesis was completely blocked in the presence of NS-398 at both concentrations.
Samples were run as duplicates, and values are represented as mean ± SEM of (a) five and (b) three independent experiments. Data is presented in terms
of fold change compared to cytokine levels following IL-1β treatment. Statistical analyses was performed using Students t test and one-way
ANOVA (*p< 0.05)
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related to neuropathology such as neurodenegration,
disruption of blood-brain barrier, angiogenesis, and ele-
vated complement proteins [26, 27]. Importantly, IL-6-
deficient mice have been shown to be resistant to experi-
mental autoimmune encephalomyelitis (EAE) and dis-
play impaired macrophage activation in models of brain
injury [28, 29]. Hence, it is likely that the increased IL-6
release by activated human astrocytes, especially in com-
bination with TNF-α, may contribute to deleterious ef-
fects on neuronal tissue in this context.
The immunoregulatory effects of nicotine on the per-
ipheral innate immune cells have been well established
[30–32], and similar effects on glial cells during neuroin-
flammation were observed, both in vitro [5, 7, 33] and in
vivo [34]. However, most of these observations were
made in murine astrocytes and might not necessarily
replicate the exact inflammatory environment in human
CNS pathology. Given the fact that murine and human
astrocytes respond differently to LPS [21], such differ-
ences may complicate understanding astrocyte neuroin-
flammatory properties and translational research in
human neurodegenerative diseases.
In the present study, the peak for IL-1β-induced IL-6
production occurred after 20 h incubation and this time
point was then used in the following pharmacological
experiments. We could detect a strong inhibitory effect
of nicotine on IL-1β-induced IL-6 release whereas
nicotine alone had no such effects. This is in line with
the cholinergic system not being constitutively acting as
an immune regulator on non-activated cells but rather
having a role for regulating excess of inflammation, as
potentially induced through nearby tissue damage or
other causes of local immune activation.
It is well documented that the presence of IL-1β in the
environment induces astrocytes to produce IL-8, a che-
mokine involved in neutrophil infiltration into the CNS
and pain [35]. Earlier, conflicting results have been
reported on nicotine as an inducer [36, 37] or suppressor
of IL-8 synthesis in other different cell types [38]. While
nicotine has been shown to inhibit IL-8 synthesis in rat
astrocytes [33], there are no previous data on human
astrocytes. We found a strong inhibitory effect of high
doses of nicotine (100 μM) on IL-8 released by activated
human astrocytes. This is in line with earlier findings that
nicotine pretreatment was shown to protect mice sub-
jected to kidney ischemia injury by preventing neutrophil
recruitment through attenuation of KC/CXCL1, a neutro-
phil chemoattractant [39]. Also, nicotine has been shown
to exert similar effects on IL-8 in fibroblast-like synovio-
cytes derived from rheumatoid arthritis patients [40].
Altogether, the immune-suppressive effects of nicotine on
IL-8 release from astrocytes in the present study hold
therapeutic implications in protecting the CNS from the
immunological escalation following leucocyte infiltration.
We could also observe a reduction in IL-13 levels
which is mainly a Th2 response-promoting cytokine
shown to have anti-inflammatory effects during neuroin-
flammation [41], and its downregulation in response to
nicotine needs further investigation. It is also important
to point out that IL-1β neither induced other Th2
cytokines such as IL-2 and IL-4 nor affected the anti-
inflammatory cytokine IL-10 in our study.
AChE is primarily expressed in neurons, and in
astrocytes, the expression of AChE is low, except in
astrocytic tumors [42, 43]. In addition, studies have also
shown AChE to exhibit very little catalytic activity in
spite of AChE protein expression being detected in
primary astrocytes [44, 45]. On the contrary, butyrylcho-
linesterase (BuChE) seems to be strongly associated with
glial cells such as astrocytes [46]. In line with earlier
studies, we were able to detect BuChE but not AChE
protein expression in the culture supernatants when
treated with IL-1β and nicotine. In addition, we
observed a tendency with increasing nicotine treatment
to reduce BuChE protein levels. In support of our
findings, Darreh-Shori et al. [47] have published similar
results showing decreased BuChE protein expression
and activity with increasing acetylcholine treatment
whereas no such effects were observed in the case of












Fig. 9 Schematic representation of the immunomodulatory effects
of nicotine on human fetal astrocytes. During neuroinflammation,
proinflammatory cytokines such as IL-1β stimulate the production of
NF-κB-dependent cytokines such as IL-6 and TNF-α. In our study,
we observed that nicotine treatment inhibits the production of such
inflammatory cytokines possibly through the COX-2 pathway to
restore homeostasis. Nicotine binds to its α7nACh receptor on
astrocytes and increases a COX-2-dependent PGE2 level that seems
to be a crucial mechanism
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expression during inflammation cannot be overlooked,
owing to its low expression/activity in human primary
astrocytes, we hypothesize that AChE might not produce
any notable effects on the cytokine production of
activated primary astrocytes. On the other hand, the
association of elevated cortical BuChE levels with
Alzheimer’s disease [46] and stroke [48] make nicotine’s
inhibitory effect on BuChE activity beneficial in prevent-
ing ACh degradation, limiting astrogliosis, and eventu-
ally suppressing neuroinflammation.
Nicotine may act on several receptors, and it has to be
noted that several nicotine receptor subtypes are expressed
on astrocytes [33, 49]. In the present study, we believe it is
likely that α7nAChR alone is mediating the immune-
suppressive effects of nicotine, for a number of reasons.
First, among the other subtypes of nicotine receptors,
α7nAChR is the crucial nicotinic receptor mediating anti-
inflammatory effects [10, 50, 51] and a key mediator of the
nicotinic anti-inflammatory pathway in inflammatory
diseases [32, 52]. Moreover, α7nAChR activation has been
shown to protect astrocytes from oxidative stress-induced
death by inhibiting the mitochondrial apoptotic pathway
and thus is implicated in providing neuroprotection against
several neuroinflammatory diseases [18, 53, 54]. Second, we
could detect the expression of α7nAChR on the human
astrocytes, and the specificity was further confirmed by
double staining with GFAP, showing that all of these
activated cells displayed strong expression of α7nAChR.
While the beneficial effects of α7nAChR activation in
combating neuroinflammation have been widely studied,
the exact mechanism by which such an effect is elicited re-
mains elusive. Mechanistic studies on the activation of
α7nAChR on microglia have been shown to resolve inflam-
mation through COX-2 and PGE2 up-regulation [6]. Our
results from PG analysis and COX-2 inhibition studies sug-
gest that a similar mechanism is triggered upon α7nAChR
activation in astrocytes. In peripheral monocytes, Takahashi
et al. [55] have shown that in vitro treatment with nicotine
induced an increase in PGE2 levels in a COX-2-dependent
manner, which in turn interacted with its EP2/4 receptors
in an autocrine/paracrine fashion. The same group has also
shown that activation of EP2/4 receptors led to an increase
in secondary messenger cyclic adenosine monophosphate
(cAMP) and protein kinase A activity, thereby inhibiting
IL-18 production. Interestingly, and like nicotine, PGs have
been shown to have major impact on neuroinflammation,
for example, illustrated by earlier in vivo data that COX-2-
deficient mice exhibited an aggravated neuroinflammatory
response following intracerebroventricular LPS injection
[56]. Altogether, our results thus implicate that cholinergic
regulation of astrocytes, and potential neuroprotection,
might be partly mediated via COX-2-dependent endogen-
ous PGE2 production. In this context, it may be noted that
non-steroidal anti-inflammatory drugs (NSAIDs) are small
lipid molecules and are known to pass the blood-brain
barrier [57]. Given the results of the present study, these
drugs may exert important effects on activated resident
cells of the CNS and also regulate cholinergic mechanisms.
Whether these mechanisms also may affect neurosignaling
or other brain functions is not yet known.
Astrocytes are well known for their constant interaction
with microglia, and soluble factors released by astrocytes
are known to regulate microglial activity. Studies by Min et
al. [58] have clearly documented the modulatory role of as-
trocytes to rescue reactive microglia from oxidative stress
by inducing expression of heme oxygenase-1, thereby limit-
ing microglial reactive oxygen species levels. It is also im-
portant to note that both PGE2 and conditioned medium
from astrocytes have been shown to attenuate IL-12 cyto-
kine release by activated microglia and thus inhibit Th1 im-
mune responses in CNS autoimmune diseases [59]. In
conclusion, nicotine treatment can not only control astro-
gliosis but may also have potential indirect effects on other
activated brain cells such as microglia and thus provide
dampening of excessive inflammation and damage.
Conclusions
Reactive astrogliosis has been implicated in the disease
progression of several neurodegenerative diseases such
as Alzheimer’s disease, amyotrophic lateral sclerosis,
Parkinson’s disease, and Huntington’s disease. Though
both microglia and astrocytes contribute to disease
pathology, their abundance and long-lasting role during
the late stages of neuroinflammation make astrogliosis
the obvious therapeutic target [60]. Cholinergic agonists
could thus be clinically important in controlling
neuroinflammation by reducing reactive astrogliosis and
thereby delay neurodegeneration. Moreover, as we and
others have shown the importance of prostaglandins in
central cholinergic mechanisms, these data give implica-
tions that in addition to its well-documented peripheral
effects on pain mediators, NSAIDs may also exert
central nervous effects, also on central pain regulation,
which demands further investigations in this context.
In summary, we have shown that activation of primary
human fetal astrocytes with IL-1β results in reactive astro-
gliosis accompanied by the up-regulation of several proin-
flammatory cytokines. Treatment with nicotine inhibited
not only cytokines such as IL-6, TNF-α, and IL-1β but also
downregulated pivotal inflammatory mediators such as
IL-8 and BuChE. Interestingly, the neuroprotective effects
of nicotine were mediated by α7nAChR activation
resulting in subsequent COX-2-dependent PGE2 produc-
tion. These results confirm the potential for cholinergic
neuroprotection and implicate an important role for the
prostaglandin system in cholinergic regulatory effects,
possibly important for the development of future thera-
peutic strategies of neuroinflammation.
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